{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:50:44Z","timestamp":1791489044865,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Research in mastocytosis, characterized by clonal expansion of mast cells (MC), and driven by the KIT D816V mutation in &gt;90% of patients, has been hampered by the lack of in vivo models. Here, we describe a novel knock-in mouse line expressing Kit D814V (murine homolog to human KIT D816V) in the hematopoietic compartment by Scl-CreER-mediated recombination. Scl-Cre;Kit\n                    <jats:sup>D814V fl\/+<\/jats:sup>\n                    mice presented increased MC progenitors in the bone marrow (BM) leading to MC expansion in the skin, stomach, spleen and liver, and increased serum levels of murine MC protease-1 (mMCP-1) and mMCP-6. Additionally, mice exhibited a myeloid neoplasm with leukocytosis, erythrocytosis, extramedullary hematopoiesis, and hepatosplenomegaly. In competitive BM transplantation, Kit D814V cells had a proliferative advantage over wild-type cells, resulting in increased MC, leukocytosis, erythrocytosis, and extramedullary hematopoiesis in recipient mice. Treatment of transplanted mice with a KIT-targeting tyrosine kinase inhibitor was able to control the mutant clone, and led to significant reduction of skin MC, leukocytes as well as reticulocytes, and normalization of spleen weight. In conclusion, we describe here a novel mouse model presenting a phenotype closely resembling human systemic mastocytosis with associated hematologic neoplasm (SM-AHN), which could help in clarifying the pathogenesis of mastocytosis and exploring novel therapeutic strategies.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-03141-8","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:22:11Z","timestamp":1791440531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generation of a novel knock-in mouse line expressing oncogenic Kit D814V in the hematopoietic stem cell compartment as a preclinical model for systemic mastocytosis"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1549-8932","authenticated-orcid":false,"given":"Simona","family":"Stivala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-5902","authenticated-orcid":false,"given":"Alina","family":"Makeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Almeida Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etnik","family":"Sheremeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8464-6120","authenticated-orcid":false,"given":"Laetitia","family":"Clauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Usart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-9258","authenticated-orcid":false,"given":"Ewelina M.","family":"Bartoszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Pelczar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-3119","authenticated-orcid":false,"given":"Martina","family":"Konantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-8226","authenticated-orcid":false,"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"3141_CR1","doi-asserted-by":"crossref","unstructured":"Akin C, Arock M, Carter MC, George TI, Valent P. Mastocytosis. Nat Rev Dis Primers. 2025;11:1\u201322.","DOI":"10.1038\/s41572-025-00611-8"},{"key":"3141_CR2","doi-asserted-by":"crossref","unstructured":"Valent P, Hartmann K, Hoermann G, Reiter A, Alvarez-Twose I, Brockow K, et al. Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM\/ECNM. J Allergy Clin Immunol Pract 2024;12:3250\u20133260.e5.","DOI":"10.1016\/j.jaip.2024.08.044"},{"key":"3141_CR3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.jaci.2021.04.013","volume":"148","author":"CF Schuler","year":"2021","unstructured":"Schuler CF, Volertas S, Khokhar D, Yuce H, Chen L, Baser O, et al. Prevalence of mastocytosis and hymenoptera venom allergy in the United States. J Allergy Clin Immunol. 2021;148:1316\u201323.","journal-title":"J Allergy Clin Immunol"},{"key":"3141_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/1651-226X.2024.31406","volume":"63","author":"A Bergstr\u00f6m","year":"2024","unstructured":"Bergstr\u00f6m A, H\u00e4gglund H, Berglund A, Nilsson G, Lambe M. Epidemiology of mastocytosis: a population-based study (Sweden). Acta Oncol. 2024;63:44\u201350.","journal-title":"Acta Oncol"},{"key":"3141_CR5","doi-asserted-by":"publisher","first-page":"E646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5:E646.","journal-title":"Hemasphere"},{"key":"3141_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","volume":"137","author":"K Hartmann","year":"2016","unstructured":"Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, \u00c1lvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35\u201345.","journal-title":"J Allergy Clin Immunol"},{"key":"3141_CR7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"3141_CR8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"3141_CR9","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"K-H Lim","year":"2009","unstructured":"Lim K-H, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727\u201336.","journal-title":"Blood"},{"key":"3141_CR10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1172\/JCI116761","volume":"92","author":"T Furitsu","year":"1993","unstructured":"Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Investig. 1993;92:1736\u201344.","journal-title":"J Clin Investig"},{"key":"3141_CR11","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA. 1995;92:10560\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3141_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","volume":"138","author":"A Orfao","year":"2007","unstructured":"Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007;138:12\u201330.","journal-title":"Br J Haematol"},{"key":"3141_CR13","doi-asserted-by":"crossref","unstructured":"Hoermann G, Orfao A, Lyons JJ, Chantran Y, Broesby-Olsen S, Sabato V, et al. Impact of molecular evaluations in the biology, diagnosis, and prognostication of patients with mastocytosis. J Allergy Clin Immunol Pract 2026;14:1\u201316.","DOI":"10.1016\/j.jaip.2025.07.055"},{"key":"3141_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jaci.2022.04.012","volume":"149","author":"M Tsai","year":"2022","unstructured":"Tsai M, Valent P, Galli SJ. KIT as a master regulator of the mast cell lineage. J Allergy Clin Immunol. 2022;149:1845\u201354.","journal-title":"J Allergy Clin Immunol"},{"key":"3141_CR15","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","volume":"112","author":"N Harir","year":"2008","unstructured":"Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lanner\u00e9e S, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade. Blood. 2008;112:2463\u201373.","journal-title":"Blood"},{"key":"3141_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/bjh.18116","volume":"202","author":"V Rajan","year":"2023","unstructured":"Rajan V, Prykhozhij SV, Pandey A, Cohen AM, Rainey JK, Berman JN. KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis. Br J Haematol. 2023;202:960\u201370.","journal-title":"Br J Haematol"},{"key":"3141_CR17","doi-asserted-by":"crossref","unstructured":"Pathania S, Pentik\u00e4inen OT, Singh PK A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors. Biochim Biophys Acta Rev Cancer. 2021;1876:188631.","DOI":"10.1016\/j.bbcan.2021.188631"},{"key":"3141_CR18","doi-asserted-by":"crossref","unstructured":"Obata Y, Toyoshima S, Wakamatsu E, Suzuki S, Ogawa S, Esumi H, et al. Oncogenic Kit signals on endolysosomes and the endoplasmic reticulum are essential for neoplastic mast cell proliferation. Nat Commun. 2014;10:5715.","DOI":"10.1038\/ncomms6715"},{"key":"3141_CR19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.V98.5.1365","volume":"98","author":"RJ Chian","year":"2001","unstructured":"Chian RJ, Young S, Danilkovitch-Miagkova A, R\u00f6nnstrand L, Leonard E, Ferrao P, et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood. 2001;98:1365\u201373.","journal-title":"Blood"},{"key":"3141_CR20","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460\u20136.","journal-title":"Blood"},{"key":"3141_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bjh.20214","volume":"207","author":"X Sun","year":"2025","unstructured":"Sun X, Wang C, Metcalfe DD, Carter MC, Maric I. Prevalence of myeloid gene alterations in paediatric cutaneous and systemic mastocytosis. Br J Haematol. 2025;207:455\u201362.","journal-title":"Br J Haematol"},{"key":"3141_CR22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.jaci.2022.04.004","volume":"149","author":"M Arock","year":"2022","unstructured":"Arock M, Hoermann G, Sotlar K, Hermine O, Sperr WR, Hartmann K, et al. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. J Allergy Clin Immunol. 2022;149:1855\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"3141_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13578-016-0120-8","volume":"6","author":"H Ke","year":"2016","unstructured":"Ke H, Kazi JU, Zhao H, Sun J. Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis. Cell Biosci. 2016;6:55.","journal-title":"Cell Biosci"},{"key":"3141_CR24","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","volume":"28","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017;28:2367\u201376.","journal-title":"Ann Oncol"},{"key":"3141_CR25","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530\u201341.","journal-title":"N Engl J Med"},{"key":"3141_CR26","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","volume":"6","author":"A Reiter","year":"2022","unstructured":"Reiter A, Schwaab J, DeAngelo DJ, Gotlib J, Deininger MW, Pettit KM, et al. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv. 2022;6:5750\u201362.","journal-title":"Blood Adv"},{"key":"3141_CR27","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27:2183\u201391.","journal-title":"Nat Med"},{"key":"3141_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","volume":"146","author":"K Hartmann","year":"2020","unstructured":"Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E, et al. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020;146:356\u2013366.e4.","journal-title":"J Allergy Clin Immunol"},{"key":"3141_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107919","volume":"157","author":"A Reiter","year":"2025","unstructured":"Reiter A, Gotlib J, \u00c1lvarez-Twose I, Radia DH, L\u00fcbke J, Bobbili PJ, et al. Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: a retrospective real-world external control study. Leuk Res. 2025;157:107919.","journal-title":"Leuk Res"},{"key":"3141_CR30","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.jaip.2025.05.026","volume":"13","author":"M Castells","year":"2025","unstructured":"Castells M, Akin C, Hartmann K, Broesby-Olsen S, George TI, Powell D, et al. Continued symptom and quality of life improvement with favorable safety shown with long-term avapritinib in indolent systemic mastocytosis. J Allergy Clin Immunol Pr. 2025;13:2194\u20132196.e1.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"3141_CR31","first-page":"EVIDoa2200339","volume":"2","author":"G Jason","year":"2023","unstructured":"Jason G, Mariana C, Oude EH, Frank S, Karin H, Sigurd B-O, et al. Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid. 2023;2:EVIDoa2200339.","journal-title":"NEJM Evid"},{"key":"3141_CR32","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3324\/haematol.2018.195867","volume":"103","author":"M Arock","year":"2018","unstructured":"Arock M, Wedeh G, Hoermann G, Bibi S, Akin C, Peter B, et al. Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. Haematologica. 2018;103:1760\u201371.","journal-title":"Haematologica"},{"key":"3141_CR33","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20050807","volume":"202","author":"JP Zappulla","year":"2005","unstructured":"Zappulla JP, Dubreuil P, Desbois S, L\u00e9tard S, Hamouda NBen, Da\u00ebron M, et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med. 2005;202:1635\u201341.","journal-title":"J Exp Med"},{"key":"3141_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep41427","volume":"7","author":"N Pelusi","year":"2017","unstructured":"Pelusi N, Kosanke M, Riedt T, R\u00f6sseler C, Ser\u00e9 K, Li J, et al. The spleen microenvironment influences disease transformation in a mouse model of KITD816V-dependent myeloproliferative neoplasm. Sci Rep. 2017;7:41427.","journal-title":"Sci Rep"},{"key":"3141_CR35","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/blood-2008-11-189605","volume":"117","author":"A Gerbaulet","year":"2011","unstructured":"Gerbaulet A, Wickenhauser C, Scholten J, Peschke K, Drube S, Horny H-P, et al. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood. 2011;117:2012\u201321.","journal-title":"Blood"},{"key":"3141_CR36","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1182\/blood-2004-08-3037","volume":"105","author":"JR G\u00f6thert","year":"2005","unstructured":"G\u00f6thert JR, Gustin SE, Hall MA, Green AR, G\u00f6ttgens B, Izon DJ, et al. In vivo fate-tracing studies using the Scl stem cell enhancer: Embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood. 2005;105:2724\u201332.","journal-title":"Blood"},{"key":"3141_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"3141_CR38","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Bucht Thorsen S, Ekman D, et al. Homogenous 96-Plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9:e95192.","journal-title":"PLoS One"},{"key":"3141_CR39","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1093\/nar\/gkr424","volume":"39","author":"M Lundberg","year":"2011","unstructured":"Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011;39:e102\u2013e102.","journal-title":"Nucleic Acids Res"},{"key":"3141_CR40","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S0002-9440(10)62055-X","volume":"167","author":"MA Grimbaldeston","year":"2005","unstructured":"Grimbaldeston MA, Chen C-C, Piliponsky AM, Tsai M, Tam S-Y, Galli SJ. Mast cell-deficient W-sash c-kit mutant KitW-sh\/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005;167:835\u201348.","journal-title":"Am J Pathol"},{"key":"3141_CR41","doi-asserted-by":"crossref","unstructured":"Conde E, Lamanna E, Mougel A, J Kamphuis JB, Loste A, et al. A vaccine targeting human IgE induces long-term protection against anaphylaxis in humanized mice. Sci Transl Med. 2025;17:eads0982.","DOI":"10.1126\/scitranslmed.ads0982"},{"key":"3141_CR42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/modpathol.2010.224","volume":"24","author":"K Sotlar","year":"2011","unstructured":"Sotlar K, Cerny-Reiterer S, Petat-Dutter K, Hessel H, Berezowska S, M\u00fcllauer L, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol. 2011;24:585\u201395.","journal-title":"Mod Pathol"},{"key":"3141_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1155\/1998\/341340","volume":"16","author":"L Escribano","year":"1998","unstructured":"Escribano L, Orfao A, Villarrubia J, D\u00edaz-Agust\u00edn B, Cerver\u00f3 C, Rios A, et al. Immunophenotypic characterization of human bone marrow mast cells. a flow cytometric study of normal and pathological bone marrow samples. Anal Cell Pathol. 1998;16:151\u20139.","journal-title":"Anal Cell Pathol"},{"key":"3141_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/335088a0","volume":"335","author":"B Chabot","year":"1988","unstructured":"Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 1988;335:88\u201389.","journal-title":"Nature"},{"key":"3141_CR45","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1182\/blood.2021014612","volume":"140","author":"J Gotlib","year":"2022","unstructured":"Gotlib J, Reiter A, DeAngelo DJ. Avapritinib for advanced systemic mastocytosis. Blood. 2022;140:1667\u201373.","journal-title":"Blood"},{"key":"3141_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/JBM.S366367","volume":"15","author":"D Tremblay","year":"2024","unstructured":"Tremblay D, Wagner N, Mascarenhas J. Management of advanced systemic mastocytosis: clinical challenges. J Blood Med. 2024;15:421\u201333.","journal-title":"J Blood Med"},{"key":"3141_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","volume":"12","author":"JH Butterfield","year":"1988","unstructured":"Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345\u201355.","journal-title":"Leuk Res"},{"key":"3141_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","volume":"124","author":"R Saleh","year":"2014","unstructured":"Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, et al. A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. Blood. 2014;124:111\u201320.","journal-title":"Blood"},{"key":"3141_CR49","doi-asserted-by":"crossref","unstructured":"Molfetta R, Lecce M, Milito ND, Putro E, Pietropaolo G, Marangio C, et al. SCF and IL-33 regulate mouse mast cell phenotypic and functional plasticity, supporting a pro-inflammatory microenvironment. Cell Death Dis 2023;14:616.","DOI":"10.1038\/s41419-023-06139-7"},{"key":"3141_CR50","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood.2023020515","volume":"143","author":"G Greiner","year":"2024","unstructured":"Greiner G, Witzeneder N, Klein K, Tangermann S, Kodajova P, Jaeger E, et al. Tumor necrosis factor \u03b1 promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis. Blood. 2024;143:1006\u201317.","journal-title":"Blood"},{"key":"3141_CR51","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jaci.2023.07.001","volume":"152","author":"M Konantz","year":"2023","unstructured":"Konantz M, Williams M, Merkel T, Reiss A, Dirnhofer S, Meyer SC, et al. Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis. J Allergy Clin Immunol. 2023;152:1019\u201324.","journal-title":"J Allergy Clin Immunol"},{"key":"3141_CR52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jaci.2015.07.006","volume":"137","author":"A Rabenhorst","year":"2016","unstructured":"Rabenhorst A, Leja S, Schwaab J, Gehring M, F\u00f6rster A, Arock M, et al. Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity. J Allergy Clin Immunol. 2016;137:314\u2013318.e5.","journal-title":"J Allergy Clin Immunol"},{"key":"3141_CR53","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/bloodadvances.2023011338","volume":"8","author":"S Rai","year":"2024","unstructured":"Rai S, Zhang Y, Grockowiak E, Kimmerlin Q, Hansen N, Stoll CB, et al. IL-1\u03b2 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024;8:1234\u201349.","journal-title":"Blood Adv"},{"key":"3141_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12167","volume":"12","author":"A P\u00e9rez-Pons","year":"2022","unstructured":"P\u00e9rez-Pons A, Jara-Acevedo M, Henriques A, Navarro-Navarro P, Garc\u00eda-Montero AC, \u00c1lvarez-Twose I, et al. Altered innate immune profile in blood of systemic mastocytosis patients. Clin Transl Allergy. 2022;12:e12167.","journal-title":"Clin Transl Allergy"},{"key":"3141_CR55","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jaci.2021.12.786","volume":"150","author":"MAW Hermans","year":"2022","unstructured":"Hermans MAW, Heeringa JJ, Swagemakers SGA, Schrijver B, van Daele PLA, van der Spek PJ, et al. Altered leukocyte subsets and immune proteome indicate proinflammatory mechanisms in mastocytosis. J Allergy Clin Immunol. 2022;150:146\u2013156.e10.","journal-title":"J Allergy Clin Immunol"},{"key":"3141_CR56","first-page":"45","volume":"18","author":"P Valent","year":"2025","unstructured":"Valent P, Akin C, Sperr WR, Horny H-P, Arock M, Metcalfe DD, et al. New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol Mech Dis. 2025;18:45.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"3141_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jaci.2012.11.008","volume":"132","author":"K Hartmann","year":"2013","unstructured":"Hartmann K, Wagner N, Rabenhorst A, Pflanz L, Leja S, F\u00f6rster A, et al. Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. J Allergy Clin Immunol. 2013;132:232\u2013235.e4.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03141-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:02:55Z","timestamp":1791486175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03141-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":57,"alternative-id":["3141"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03141-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS, AM, TAF, ER, LC, ES, MU, EBK and MK have no conflicts of interest to disclose. KH has consulted for and received honoraria from ALK-Abello, Allergopharma, Almirall, BioCryst, Blueprint, Cogent, Galderma, KalVista, Leo, Menarini, Novartis, Otsuka, Pfizer, Sanofi, Takeda, and Thermo Fisher.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}